Standout Papers

Type 2 diabetes mellitus 2004 2026 2011 2018 1.5k
  1. Type 2 diabetes mellitus (2015)
    Ralph A. DeFronzo, Ele Ferrannini et al. Nature Reviews Disease Primers
  2. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes (2004)
    John B. Buse, Robert R. Henry et al. Diabetes Care
  3. Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects (2006)
    Timothy E. Graham, Qin Yang et al. New England Journal of Medicine
  4. Impaired Fasting Glucose and Impaired Glucose Tolerance (2007)
    David M. Nathan, Mayer B. Davidson et al. Diabetes Care
  5. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial (2008)
    Alan J. Garber, Robert R. Henry et al. The Lancet
  6. Adiponectin: More Than Just Another Fat Cell Hormone? (2003)
    Manju Chandran, Susan A. Phillips et al. Diabetes Care
  7. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease (2013)
    Sunder Mudaliar, Robert R. Henry et al. Gastroenterology
  8. SGLT2 inhibition — a novel strategy for diabetes treatment (2010)
    Edward C. Chao, Robert R. Henry Nature Reviews Drug Discovery
  9. Acute and Chronic Effect of Insulin on Leptin Production in Humans: Studies In Vivo and In Vitro (1996)
    Jerzy W. Kolaczynski, Mark R. Nyce et al. Diabetes
  10. The expression of TNF alpha by human muscle. Relationship to insulin resistance. (1996)
    Mehrnoosh Saghizadeh, Juling Ong et al. Journal of Clinical Investigation
  11. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011)
    Ralph A. DeFronzo, Devjit Tripathy et al. New England Journal of Medicine
  12. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors (2016)
    William H. Polonsky, Robert R. Henry Patient Preference and Adherence
  13. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis (2016)
    Sunder Mudaliar, Robert R. Henry et al. Diabetes Care
  14. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes (2017)
    Satish K. Garg, Robert R. Henry et al. New England Journal of Medicine

Immediate Impact

2 by Nobel laureates 18 from Science/Nature 159 standout
Sub-graph 1 of 17

Citing Papers

Direct radical functionalization of native sugars
2024 StandoutNature
Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management
2023 Standout

Works of Robert R. Henry being referenced

Type 2 diabetes mellitus
2015 Standout
SGLT2 inhibition — a novel strategy for diabetes treatment
2010 Standout

Author Peers

Author Last Decade Papers Cites
Robert R. Henry 12368 10788 6931 288 27.0k
Ralph A. DeFronzo 18905 13264 11642 282 37.6k
Jean‐Charles Fruchart 7114 15619 5438 380 31.3k
Eleuterio Ferrannini 10351 6226 7147 165 21.1k
Matti Uusitupa 13017 6664 11559 477 36.3k
John E. Gerich 15124 7694 7417 339 25.9k
Richard E. Pratley 16147 8472 9836 392 34.6k
Michael J. Quon 6529 8847 7917 200 25.9k
Hans‐Ulrich Häring 7526 8990 8415 505 26.2k
David E. Moller 5599 16803 6743 167 25.6k
Dario Giugliano 12861 5695 8372 449 31.3k

All Works

Loading papers...

Rankless by CCL
2026